نتایج جستجو برای: alk kinase

تعداد نتایج: 231548  

Journal: :Blood 2004
Addolorata Maria Luce Coluccia Silvia Perego Loredana Cleris Rosalind Helen Gunby Lorena Passoni Edoardo Marchesi Franca Formelli Carlo Gambacorti-Passerini

Deregulated apoptosis is a common finding in tumorigenesis. The oncogenic tyrosine kinase nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) delivers a strong survival signal in anaplastic large cell lymphomas (ALCLs). Although NPM/ALK activates multiple antiapoptotic pathways, the biologic relevance and therapeutic potential of more downstream apoptotic effectors are mostly unknown. In this re...

Journal: :Cancer research 2005
Mariko Watanabe Masataka Sasaki Kinji Itoh Masaaki Higashihara Kazuo Umezawa Marshall E Kadin Lawrence J Abraham Toshiki Watanabe Ryouichi Horie

High expression of CD30 and JunB is characteristic of tumor cells in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL). Possible interactions of CD30 and JunB were examined in this study. We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)-positive and NPM-ALK-negative ALCL and HL is regulated by a constitutively active CD30-...

2016
Yongfeng Wang Long Wang Shan Guan Wenming Cao Hao Wang Zhenghu Chen Yanling Zhao Yang Yu Huiyuan Zhang Jonathan C. Pang Sophia L. Huang Yo Akiyama Yifan Yang Wenjing Sun Xin Xu Yan Shi Hong Zhang Eugene S. Kim Jodi A. Muscal Fengmin Lu Jianhua Yang

ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK re...

Journal: :Blood 2003
Randy D Gascoyne Laurence Lamant Jose I Martin-Subero Valia S Lestou Nancy Lee Harris Hans-Konrad Müller-Hermelink John F Seymour Lynda J Campbell Douglas E Horsman Isabelle Auvigne Estelle Espinos Reiner Siebert Georges Delsol

Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL). All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners. A rare variant of diffuse large B-...

Journal: :Cancer research 2000
M Trinei L Lanfrancone E Campo K Pulford D Y Mason P G Pelicci B Falini

Anaplastic lymphoma kinase (ALK)-positive lymphomas ("ALKomas") constitute a distinct molecular and clinicopathological entity within the heterogeneous group of CD30-positive large cell lymphomas. In 80-85% of cases tumor cells express a Mr 80,000 hybrid protein comprising the nucleolar phosphoprotein nucleophosmin (NPM) and the ALK. We report here the cloning and expression of a novel ALK-fusi...

Journal: :Cancer research 2014
Arata Tomiyama Takamasa Uekita Reiko Kamata Kazuki Sasaki Junko Takita Miki Ohira Akira Nakagawara Chifumi Kitanaka Kentaro Mori Hideki Yamaguchi Ryuichi Sakai

Neuroblastomas harbor mutations in the nonreceptor anaplastic lymphoma kinase (ALK) in 8% to 9% of cases where they serve as oncogenic drivers. Strategies to reduce ALK activity offer clinical interest based on initial findings with ALK kinase inhibitors. In this study, we characterized phosphotyrosine-containing proteins associated with ALK to gain mechanistic insights in this setting. Flotill...

2016
Claudia Voena Lydia M. Varesio Liye Zhang Matteo Menotti Teresa Poggio Elena Panizza Qi Wang Valerio G. Minero Sharmila Fagoonee Mara Compagno Fiorella Altruda Stefano Monti Roberto Chiarle

A subset of Non-Small Cell Lung Carcinoma (NSCLC) carries chromosomal rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene. ALK-rearranged NSCLC are typically adenocarcinoma characterized by a solid signet-ring cell pattern that is frequently associated with a metastatic phenotype. Recent reports linked the presence of ALK rearrangement to an epithelial-mesenchymal transition (EMT...

2013
Kamaraj Sattu Falko Hochgräfe Jianmin Wu Ganesh Umapathy Christina Schönherr Kristina Ruuth Damini Chand Barbara Witek James Fuchs Pui-Kai Li Fredrik Hugosson Roger J Daly Ruth H Palmer Bengt Hallberg

Activation of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is a key oncogenic mechanism in a growing number of tumor types. In the majority of cases, ALK is activated by fusion with a dimerizing partner protein as a result of chromosomal translocation events, most studied in the case of the nucleophosmin-ALK and echinoderm microtubule-associated protein-like 4-ALK oncoproteins....

Journal: :Biochemical and biophysical research communications 2014
Fei Xu Hongling Li Yong Sun

Neuroblastoma (NB) patients harboring mutated ALK can be expected to potentially benefit from targeted therapy based on ALK tyrosine kinase inhibitor (TKI), such as crizotinib and ceritinib. However, the effect of the treatment varies with different individuals, although with the same genic changes. Axl receptor tyrosine kinase is expressed in a variety of human cancers, but little data are rep...

2014
Arata Tomiyama Takamasa Uekita Reiko Kamata Kazuki Sasaki Junko Takita Miki Ohira Akira Nakagawara Chifumi Kitanaka Kentaro Mori Hideki Yamaguchi Ryuichi Sakai

Neuroblastomas harbor mutations in the nonreceptor anaplastic lymphoma kinase (ALK) in 8% to 9% of cases where they serve as oncogenic drivers. Strategies to reduce ALK activity offer clinical interest based on initial findings with ALK kinase inhibitors. In this study, we characterized phosphotyrosine-containing proteins associated with ALK to gain mechanistic insights in this setting. Flotill...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید